Company Information

    Celularity was founded on July 2017. The company is based in Warren, NJ, USA . The number of employees in Celularity is less than 250. Celularity is a clinical-stage cell therapeutics company delivering transformative allogeneic cellular therapies.
      If you are the founder or part of the founding team, please tell the world your story


          Funding & investors

          Celularity has received 2 rounds of venture funding. The total funding amount is around $290M.

            Similar Companies [beta]

              Venture Categories

                Active Venture Investors




                  Venture Competitors

                    News

                        Celularity - Blog

                          • Celularity Enters into Multi-Year Strategic Partnership with Palantir Technologies

                          • Celularity to leverage Palantir’s next generation software and computational capabilities with their deep cellular data set to accelerate research and development activities Partnership includes equity investment by Palantir in Celularity Investment, combined with previously announced PIPE investment, brings over $100 million in new funding to Celularity FLORHAM PARK, N.J., May 05, 2021 (GLOBE NEWSWIRE) — Celularity Inc. (“Celularity”), a clinical-stage biotechnology company leading the next evolution in cellular medicine with the development of off-the-shelf allogeneic […]
                          • GX Acquisition Corp. Provides Information Regarding Extension of Deadline to Complete Celularity Business Combination

                          • NEW YORK, April 16, 2021 /PRNewswire/ — On April 14, 2021, GX Acquisition Corp. (“GX”) (NASDAQ: “GXGX”), provided information regarding a proposal to amend GX’s amended and restated certificate of incorporation (the “Charter”) to extend the date by which GX has to complete its initial business combination (the “Extension”) from May 23, 2021 to July 31, 2021. The Charter currently provides that GX has 24 months from the closing of its initial public offering (until May 23, 2021) to complete an initial business […]
                          • Celularity Gains FDA Orphan Drug Status on Strength of Placental Stem Cell Trials

                          • On Tuesday, Celularity received Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) for its off-the-shelf natural killer cell therapy for malignant gliomas. The news coincided with the American Association for Cancer Research (AACR) Annual Meeting 2021, where Celularity delivered an oral presentation and two posters. Each showcased the viability of that therapeutic compound, CYNK-001, as a treatment for multiple, disparate indications. The presentations focused on CYNK-001 as an off-the-shelf therapeutic for both COVID-19 and […]
                          • Celularity Receives Orphan Drug Designation for Natural Killer Cell Therapy CYNK-001 in the Treatment of Malignant Gliomas

                          • FLORHAM PARK, N.J., April 13, 2021 (GLOBE NEWSWIRE) — Celularity Inc. (“Celularity”), a clinical-stage biotechnology company, leading the next evolution in cellular medicine with the development of off-the-shelf allogeneic therapies derived from the postpartum human placenta, announced today the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to the company’s non-genetically modified cryopreserved human placental hematopoietic stem cell-derived natural killer (NK) cell therapy, CYNK-001, for the treatment of patients with malignant gliomas. […]
                          • Celularity Announces Multiple Presentations at the American Association for Cancer Research (AACR) Annual Meeting 2021

                          • Presentations to showcase updates related to multiple Celularity programs in immuno-oncology and infectious disease FLORHAM PARK, N.J., April 09, 2021 (GLOBE NEWSWIRE) — Celularity Inc. (“Celularity”), a clinical-stage biotechnology company, leading the next evolution in cellular medicine with the development of off-the-shelf allogeneic therapies derived from the postpartum human placenta, will display multiple presentations at the American Association for Cancer Research (AACR) Annual Meeting 2021. The presentations include one poster highlighting early clinical data of […]
                          • CBLB ablation with CRISPR/Cas9 enhances cytotoxicity of human placental stem cell-derived NK cells for cancer immunotherapy

                          Share:     facebook    twitter    linkedin    reddit    email

                            Ventures Media is one of the largest startup and venture capital communities for startup and venture capital funding information and analysis.

                            Leave a Reply

                            Your email address will not be published. Required fields are marked *